Insurers and pharmacy benefit managers (PBMs) are joining forces and engaging major drug manufacturers in risk-based deals where they would be penalized if their products don’t perform as expected. This move comes as pharmaceutical pricing for many new drugs has reached truly astounding heights, often times without being able to produce any long-term benefits data. See what conditions are being specifically targeted and find out more here. Login required to read more. (Source: Modern Healthcare, 2016)
You are here: / / Should Drugmakers Pay When Their Products Fail?